Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.40 |
| ▸ | STK10 | O94804 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23235835 | 0.99 | MRGPRX4 (0.50) | MRGPRX4ARS1PR1S1PR5HTR6 | |
| SCHEMBL23541195 | 0.88 | MRGPRX4 (0.43) | MRGPRX4ARSLKSTK10LRRK2 | |
| Hydrochloric Acid SCHEMBL34433935 | 0.87 | MRGPRX4 (0.42) | MRGPRX4ARSLKSTK10LRRK2 | |
| SCHEMBL23235800 | 0.85 | MRGPRX4 (0.48) | MRGPRX4ARHTR6SLC6A4 | |
| Hydrochloric Acid SCHEMBL23235782 | 0.84 | MRGPRX4 (0.47) | MRGPRX4ARHTR6SLC6A4 | |
| SCHEMBL23540967 | 0.81 | MAOB (0.59) | ARMAOB | |
| SCHEMBL1060980 | 0.81 | MAOB (0.58) | MRGPRX4S1PR5SLKSTK10MAOB | |
| SCHEMBL13439831 | 0.76 | MAOB (0.52) | MRGPRX4MAOB | |
| SCHEMBL19421176 | 0.76 | L3MBTL1 (0.48) | MRGPRX4SLC6A4MAOB | |
| SCHEMBL23541002 | 0.76 | MRGPRX4 (0.44) | MRGPRX4ARHTR6SLKSTK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3806836-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | Georgia State University Research Foundation, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-112566631-A | Amidines and amidine analogs for the treatment of bacterial infections and potentiation of antibiotics | 乔治亚州大学研究基金会 | 2021-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | MRGPRX4 546/4885AR 4411/4885S1PR1 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.